Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MYNZ 
Mainz Biomed BV (MYNZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MYNZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.27% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.55M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 2 | Beta 0.25 | 52 Weeks Range 1.30 - 16.32 | Updated Date 08/29/2025 |
52 Weeks Range 1.30 - 16.32 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -22.36 |
Earnings Date
Report Date 2025-09-03 | When - | Estimate -2.4 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2307.21% |
Management Effectiveness
Return on Assets (TTM) -80.37% | Return on Equity (TTM) -465.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4589168 | Price to Sales(TTM) 8.45 |
Enterprise Value 4589168 | Price to Sales(TTM) 8.45 | ||
Enterprise Value to Revenue 5.13 | Enterprise Value to EBITDA -2.84 | Shares Outstanding 4577850 | Shares Floating 2354746 |
Shares Outstanding 4577850 | Shares Floating 2354746 | ||
Percent Insiders 1.63 | Percent Institutions 8.4 |
Upturn AI SWOT
Mainz Biomed BV
Company Overview
History and Background
Mainz Biomed BV is a molecular genetics diagnostics company focused on the early detection of cancer. Founded with the goal of developing innovative and effective diagnostic solutions, the company has evolved by focusing on expanding its product portfolio and market reach.
Core Business Areas
- Molecular Diagnostics: Mainz Biomed develops and commercializes molecular diagnostic tests, primarily focused on colorectal cancer screening.
Leadership and Structure
The leadership team comprises experienced professionals in the fields of molecular diagnostics, finance, and business development. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- ColoAlert: ColoAlert is Mainz Biomed's flagship product, a non-invasive, at-home colorectal cancer screening test based on polymerase chain reaction (PCR) technology. Market share data is difficult to pinpoint precisely but it's relatively small compared to established players in the colon cancer screening market. Competitors include Exact Sciences (EXAS) with Cologuard, and traditional colonoscopies are also a significant form of competition.
Market Dynamics
Industry Overview
The molecular diagnostics market is experiencing significant growth, driven by increasing awareness of early disease detection, advancements in technology, and an aging population. Colorectal cancer screening, in particular, is a key area of focus.
Positioning
Mainz Biomed is positioned as a provider of convenient and accurate colorectal cancer screening solutions. Its competitive advantage lies in its non-invasive approach and use of PCR technology. They compete with established diagnostic companies offering different methodologies.
Total Addressable Market (TAM)
The global market for colorectal cancer diagnostics is estimated to be in the billions of dollars. Mainz Biomed is aiming to capture a significant share of this market through its ColoAlert test.
Upturn SWOT Analysis
Strengths
- Non-invasive testing method
- PCR-based technology offers high sensitivity
- Convenient at-home sample collection
- Focus on early cancer detection
Weaknesses
- Limited market share compared to established players
- Reliance on a single core product
- Requires significant marketing and sales efforts
- Reimbursement challenges from insurers
Opportunities
- Expanding market for colorectal cancer screening
- Increasing adoption of at-home testing
- Potential for partnerships with healthcare providers
- Further development of diagnostic tests for other cancers
Threats
- Competition from established diagnostic companies
- Regulatory hurdles and approval processes
- Changes in reimbursement policies
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- EXAS
- BRLI
- CGDX
Competitive Landscape
Mainz Biomed faces intense competition from established players with greater resources and brand recognition. To succeed, it must effectively market its ColoAlert test and differentiate itself based on convenience, accuracy, and cost-effectiveness. Overcoming market acceptance and regulatory hurdles remains essential for gaining market share.
Growth Trajectory and Initiatives
Historical Growth: Without proprietary financial data, discussing historical revenue and growth trends is not possible.
Future Projections: Analyst estimates would need to be gathered to provide future growth projections.
Recent Initiatives: Recent initiatives need to be checked and validated to include in the analysis
Summary
Mainz Biomed BV is a promising molecular diagnostics company focused on the early detection of colorectal cancer. Their ColoAlert test offers a convenient non-invasive screening option, but they face stiff competition from larger, more established players like Exact Sciences. Success depends on increasing market penetration, expanding their product portfolio, and navigating regulatory hurdles. Financials are needed to show progress.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Publicly Available Information
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Market share figures are estimates and may not be precise. A more thorough review with access to financial statements is necessary for a complete evaluation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mainz Biomed BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | CEO & Executive Director Mr. Guido Baechler | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 19 | Website https://mainzbiomed.com |
Full time employees 19 | Website https://mainzbiomed.com | ||
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.